Management Team

Katrien Reynders-Frederix joined Pan Cancer T since the foundation in September 2020 as Chief Executive Officer.

Mrs. Reynders brings 16 years of international experience in the life science industry, including Biotech. She started her career as a research coordinator and evolved into leadership roles. She led teams and global drug development programs in various indications, notably in the IO field, and at different stages from clinical candidate up to market access. In a previous role, she was program director at Celyad where she oversaw the program strategy and development of the autologous CAR-T lead asset CYAD-01. Prior joining Pan Cancer T, she supported research groups at the KU Leuven with Business Development.

Mrs. Reynders holds a Master of Biomedical Sciences at the KU Leuven Belgium, a postgraduate in Business Administration from KU Leuven Belgium and is certified in project management and change management.

Prof. Reno Debets is founder and Chief Scientific Officer of Pan Cancer T.

Mr. Debets chairs the laboratory of Tumor Immunology, Department of Medical Oncology, as well as the Academic Center of Expertise of Tumor Immunology and Immune Therapies, within Erasmus MC. He is one of the pioneers in the field T cell gene engineering and adoptive T cell therapy; runs a highly-recognized laboratory for 20 years; has published >130 peer-reviewed manuscripts; and has been awarded multiple large EU grants in the field of adoptive T cell therapy.

He has received his MSc in Biological Sciences, University of Maastricht, the Netherlands, and his PhD in the field of inflammation, dept Immunology, Erasmus MC, Rotterdam, the Netherlands. He has worked as a postdoctoral fellow for 3 years at DNAX Research Institute, Palo Alto, CA (currently part of Merck laboratories) in the field of immunology. He is a certified Immunologist (since 2005) and professor in T cell immunity and adoptive therapy of tumors (since 2019).

Dr. Dora Hammerl is co-founder and VP Research and Development.

Ms. Hammerl brings 7 years of international experience in Immuno-oncology research. She is a member of the Debets laboratory for 5 years, and coordinates the research into PCT targets and their corresponding TCRs.

She has a background in Molecular Biology (2012, University of Vienna) and received her MSc in Biopharmaceutical Sciences (2015) from Leiden University. She worked for 1,5 year at La Jolla Institute, San Diego, CA, in the field of tumor Immunology and joined the Debets Laboratory at Erasmus MC where she obtained her PhD (2020).